These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31397840)

  • 21. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
    Venetsanopoulou AI; Pelechas E; Voulgari PV; Drosos AA
    Rheumatol Int; 2020 Aug; 40(8):1181-1191. PubMed ID: 32524301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion.
    Martín-Martínez MA; González-Juanatey C; Castañeda S; Llorca J; Ferraz-Amaro I; Fernández-Gutiérrez B; Díaz-González F; González-Gay MA
    Semin Arthritis Rheum; 2014 Aug; 44(1):1-8. PubMed ID: 24560170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 24. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.
    Amezaga Urruela M; Suarez-Almazor ME
    Curr Rheumatol Rep; 2012 Oct; 14(5):428-37. PubMed ID: 22802154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-lowering nutraceuticals update on scientific evidence.
    Derosa G; Colletti A; Maffioli P; D'Angelo A; Lupi A; Zito GB; Mureddu GF; Raddino R; Fedele F; Cicero AFG
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):845-859. PubMed ID: 32639326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinician Decision Support Tools: Advances in Lipid-Lowering Treatment Intensification.
    Marvel FA; Grant JK; Martin SS
    Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010884. PubMed ID: 38634283
    [No Abstract]   [Full Text] [Related]  

  • 28. Dyslipidaemia in rheumatoid arthritis in a tertiary care centre in Eastern India--a non-randomised trial.
    Ghosh UC; Roy A; Sen K; Kundu AK; Saha I; Biswas A
    J Indian Med Assoc; 2009 Jul; 107(7):427-30. PubMed ID: 20112843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
    Toms TE; Panoulas VF; Douglas KM; Nightingale P; Smith JP; Griffiths H; Sattar N; Symmons DP; Kitas GD
    Angiology; 2011 Feb; 62(2):167-75. PubMed ID: 20682616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.
    Arts EE; Popa CD; Den Broeder AA; Donders R; Sandoo A; Toms T; Rollefstad S; Ikdahl E; Semb AG; Kitas GD; Van Riel PL; Fransen J
    Ann Rheum Dis; 2016 Apr; 75(4):674-80. PubMed ID: 25691119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
    Day AL; Singh JA
    Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries.
    Rollefstad S; Ikdahl E; Wibetoe G; Sexton J; Crowson CS; van Riel P; Kitas GD; Graham I; Dahlqvist SR; Karpouzas G; Myasoedova E; Gonzalez-Gay MA; Sfikakis PP; Tektonidou MG; Lazarini A; Vassilopoulos D; Kuriya B; Hitchon CA; Stoenoiu MS; Durez P; Pascual-Ramos V; Galarza-Delgado DA; Faggiano P; Misra DP; Borg A; Mu R; Mirrakhimov EM; Gheta D; Myasoedova S; Krougly L; Popkova T; Tuchyňová A; Tomcik M; Vrablik M; Lastuvka J; Horák P; Medková H; Semb AG
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):539-548. PubMed ID: 34232315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 35. Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis.
    Tournadre A; Tatar Z; Pereira B; Chevreau M; Gossec L; Gaudin P; Soubrier M; Dougados M
    Int J Cardiol; 2015 Mar; 183():149-54. PubMed ID: 25666124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.
    Shirinsky I; Polovnikova O; Kalinovskaya N; Shirinsky V
    Rheumatol Int; 2013 Dec; 33(12):3045-8. PubMed ID: 23263548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study.
    Bittencourt MS; Blankstein R; Blaha MJ; Sandfort V; Agatston AS; Budoff MJ; Blumenthal RS; Krumholz HM; Nasir K
    Eur J Prev Cardiol; 2018 Nov; 25(17):1887-1898. PubMed ID: 30043629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.
    Lau CS; Chia F; Dans L; Harrison A; Hsieh TY; Jain R; Jung SM; Kishimoto M; Kumar A; Leong KP; Li Z; Lichauco JJ; Louthrenoo W; Luo SF; Mu R; Nash P; Ng CT; Suryana B; Wijaya LK; Yeap SS
    Int J Rheum Dis; 2019 Mar; 22(3):357-375. PubMed ID: 30809944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
    Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.